Zealand - announces directed issue and private placemenent
-
Zealand Pharma laver rettet emission på 6,5 mio. nye aktier
30/3 17:35
Zealand Pharma har annonceret, at selskabet går i gang med en rettet emission af cirka 6,5 mio. nye aktier gennem en accelereret bookbuilding.
Det fremgår af en fondsbørsmeddelelse torsdag eftermiddag.
Emissionen vil blive rettet mod visse institutionelle og professionelle investorer, og vil gå i gang med det samme, oplyser selskabet.
Sælges de udbudte aktier til torsdagens lukkekurs på 240,60 kr., vil det give et bruttoprovenu på knap 1,6 mia. kr.
Nettoprovenuet vil blive brugt på fortsat udvikling af Zealand Pharmas egen pipeline samt af styrke selskabets kapitalgrundlag.
Med emissionen venter Zealand Pharma at have tilstrækkelig kapital indtil midten af 2026.
Zealand Pharma oplyser, at emissionen vil gå i gang med det samme og kan være afsluttet når som helst.
Det endelige prospekt ventes offentliggjort 3. april.
.\˙ MarketWire
-
Kurs DKK 228
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary...
GlobeNewswire News Room (www.globenewswire.com)
-
6,578,948 New Shares were subscribed for in the Offering;
-
the subscription price for the New Shares is DKK 228 per New Share;
-
total gross proceeds from the Offering will amount to DKK 1.5 billion;
-
-
Zealand Pharma gennemfører aktieemission og henter 1,5 mia. kr.
31/3 06:35
Zealand Pharma har gennemført en rettet emission af cirka 6,6 mio. nye aktier gennem en accelereret bookbuilding. Der giver selskabet et bruttoprovenu på 1,5 mia. kr.
Det fremgår af en fondsbørsmeddelelse torsdag aften, efter at selskabet torsdag eftermiddag meddelte, at processen nu var i gang.
Emissionen var rettet mod institutionelle og professionelle investorer.
De i alt 6.578.948 nye aktier vil blive udstedt til 228 kr. stykket. Til sammenligning lukkede Zealand Pharma-aktien torsdag i 240,60 kr.
Nettoprovenuet vil blive brugt på fortsat udvikling af Zealand Pharmas egen pipeline samt af styrke selskabets kapitalgrundlag.
Med emissionen venter Zealand Pharma at have tilstrækkelig kapital indtil midten af 2026.
.\˙ MarketWire
-
Kan se at mit nyligt skrevne indlæg ikke er her.
Måske det bedste. Jeg er skuffet så det svier, over at Alan S. trækker sig, og at endnu en kapitalinsprøjtning finder sted. Jeg havde regnet med en SBS wonderstory, aber nicht.
Griner lidt af udtrykket ZPs Pipeline, som er SBS som aldrig virkelidhedgøres; resten er da nada.
Skuffet, JA.
Håber det bedste for jer aktionære og pas på derude. -
Hej mccarthy, Hvad mener du med med at "dit nyligt skrevne indlæg ikke er her"? Du har ikke postet et sådant kan vi se i vores log. (Vi har selvfølgelig heller ikke slettet indlægget, hvis du rent faktisk havde postet det).
Hvad mener du med, at "Alan S" trækker sig. Er det Adam Steensberg du mener?
-
Hej W435wr!Sp , Læs eventuelt med i Zealand Pharma Chatten.
-
Jeg skrev et indlæg som forsvandt. Om jeg har fumlet med tasterne eller? Og selfølgelig er det Adam S, beklager - det må være varmen hernede der driller. Og hvor er jeg ærgerlig over ZPs udmelding. Endelig troede jeg, endelig er vi næsten i mål. Nu føler jeg mig som ludobrikken der er slået hjem.
Ha' en god søndag. -
Hej mccarthy, den slags sker af og til også for mig. Især hvis det er mobilen, jeg fumler med.
Umiddelbart ser jeg ingen ændring i casen udover, at selskabet har fået bedre økonomisk polstring til de kommende år. Det betragter jeg som rettidig omhu.
Hvad mener du, at Adam Steensberg har trukket sig?
Også god søndag til dig.
-
Zealand has today completed and registered a capital increase of 6,578,948 new shares
Copenhagen, Denmark, 4 April 2023 - Further to the company announcements no. 10 and 11 / 2023, Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has today, as part of completion of a directed issue and private placement (the "Offering"), registered with the Danish Business Authority, the capital increase of approx. DKK 1.5 billion, divided into 6,578,948 ordinary shares (the "New Shares").
Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 58,582,005 divided into 58,582,005 shares with a nominal value of DKK 1 each.
The New Shares rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.
The New Shares have been issued under a temporary ISIN code and are expected to be admitted to trading on Nasdaq Copenhagen on 5 April 2023 in Zealand's permanent ISIN code DK0060257814. The temporary ISIN code is expected to be merged with the permanent ISIN code on 11 April 2023.
The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
Managers and legal counsels:
Danske Bank A/S, Goldman Sachs International, Jefferies GmbH and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators and joint bookrunners in the Offering, and Van Lanschot Kempen N.V. is acting as lead manager in the Offering (the joint global coordinators and the lead manager are jointly referred to as the "Managers").
Plesner and Cooley LLP are acting as Danish and U.S. legal advisors respectively to Zealand. Kromann Reumert is acting as legal advisor to the Managers.
Contacts:
Zealand Pharma
Anna Krassowska, Vice President, Investor Relations & Corporate Communications
[email protected]Henriette Wennicke, Executive Vice President and Chief Financial Officer
[email protected]Adam Steensberg, President and Chief Executive Officer
[email protected]About Zealand Pharma A/S
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind